Format

Send to

Choose Destination
Exp Clin Cardiol. 2001 Winter;6(4):215-21.

Role of the angiotensin II receptor blocker valsartan in heart failure.

Author information

1
Metabolic and Cardiovascular Diseases, Novartis Pharmaceuticals Corporation, Summit, New Jersey, USA; and.

Abstract

Despite an enormous amount of research carried out in the past 10 to 20 years, the role of the renin-angiotensin system in the development of heart failure is still not very well understood. This review looks at preclinical data on the role of angiotensin II as a circulating and local hormone, and the effects of stimulation of the respective receptors in heart tissue. Recent large scale clinical trials have begun to furnish evidence of the effects of blocking the renin-angiotensin system in patients with heart failure using angiotensin-converting enzyme inhibitors or, more recently, angiotensin II receptor blockers that act directly at the receptor level, independent of pathways for angiotensin II generation. Results so far indicate that there are benefits from optimizing the blockade, but open questions remain, such as the role of endothelin and bradykinins, and the extent of crosstalk between the different systems.

KEYWORDS:

Angiotensin II; Angiotensin II receptor blocker; Angiotensin-converting enzyme inhibitors; Apoptosis; Atherosclerosis; Chymase; Heart failure; Hypertension; Valsartan

PMID:
20428262
PMCID:
PMC2859003

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center